GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-26|

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer

by GeneOnline
Share To

SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ — Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. and China, respectively, in a Phase Ib/III clinical trial that evaluates the efficacy and safety of afuresertib in combination with fulvestrant, an estrogen receptor antagonist, in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer who failed after 1-2 lines of CDK4/6 inhibitors, endocrine, or chemotherapy treatments.

Afuresertib is an investigational AKT kinase inhibitor with global exclusive rights obtained from Novartis. The lead investigator of the study in China is Professor Binghe Xu, Academician of the Chinese Academy of Engineering and Director of the National Clinical Research Center for Cancer, while Professor Peter Kaufman, Lead Medical Oncologist from The University of Vermont Medical Center, is the lead investigator of the study in the U.S. Patient enrollment has begun simultaneously at the Piedmont Cancer Institute in the U.S. and Tianjin Medical University Cancer Institute & Hospital in China, and will soon begin in several other sites. Laekna will initiate a Phase III global pivotal trial after afuresertib plus fulvestrant shows a manageable safety profile in the Phase Ib study.

Breast cancer is the most common cancer among women worldwide. About 62% and 68% of all breast cancer patients in China and the U.S. are HR+/HER2- respectively[1,2]. “Although most patients with this type of breast cancer initially benefit from endocrine ±CDK4/6 inhibitors and/or chemotherapy as first- or second-line treatment, resistance occurs in most patients in about two years. I look forward to the results from the clinical study of afuresertib in combination with fulvestrant, which could offer a new treatment option for treatment-resistant breast cancer,” said Professor Xu.

“Our team has been working closely with the investigators to overcome obstacles and dose the first patients both in the U.S. and China according to schedule, which demonstrated Laekna’s robust global clinical development capabilities,” said Dr. Yong Yue, Chief Medical Officer of Laekna Therapeutics. “Our next step is to expedite simultaneous global development of afuresertib plus fulvestrant to bring hope to patients who have developed treatment resistance.”

For more information, please visit http://www.laekna.com

1 Li, Z.S., et al., Breast cancer subtypes and survival in Chinese women with operable primary breast cancer. Chin J Cancer Res, 2011. 23(2): p. 134-9.

2 SEER Cancer Stat Facts: Female Breast Cancer Subtypes. National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.htm

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top